HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5- (8- amino- 7- chloro- 2,3- dihydro- 1,4- benzodioxin- 5- yl)- 3- (1- (2- phenylethyl)- 4- piperidinyl)- 1,3,4- oxadiazol- 2(3H)- one

a 5-HT(4) receptor partial agonist; structure in first source

Also Known As:

SL 65.0155; SL-65.0155; SL65.0155

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - Oxadiazoles: 146
        5-(8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-3-(1-(2-phenylethyl)-4-piperidinyl)-1,3,4-oxadiazol-2(3H)-one: 4
  - Dioxanes
    - 5-(8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-3-(1-(2-phenylethyl)-4-piperidinyl)-1,3,4-oxadiazol-2(3H)-one: 4

Experts

1.	Cassel, J C: 1 article (07/2008)
2.	Jacquet, M: 1 article (07/2008)
3.	Jeltsch, H: 1 article (07/2008)
4.	Marchetti, E: 1 article (07/2008)
5.	Migliorati, M: 1 article (07/2008)
6.	Nivet, E: 1 article (07/2008)
7.	Roman, F S: 1 article (07/2008)
8.	Drago, Filippo: 1 article (11/2006)
9.	Leggio, Gian Marco: 1 article (11/2006)
10.	Mazzola, Carmen: 1 article (11/2006)

Related Diseases

1.	Memory Disorders (Memory Loss) 07/01/2008 - "Activation of 5-HT(4) receptors by a selective agonist such as SL65.0155 might therefore provide an opportunity to reduce learning and memory deficits associated with temporal lobe damage, and could be useful for the symptomatic treatment of memory dysfunctions related to pathological aging such as Alzheimer's disease." 02/01/2004 - "One 5-HT(4)R-directed drug (SL65.0155) is already in phase II to treat patients suffering from memory deficits or dementia."
2.	Dementia (Dementias) 02/01/2004 - "One 5-HT(4)R-directed drug (SL65.0155) is already in phase II to treat patients suffering from memory deficits or dementia." 08/01/2002 - "Its broad range of activity in cognitive tests and synergism with cholinesterase inhibitors suggest that SL65.0155 represents a promising new agent for the treatment of dementia."
3.	Amnesia (Dissociative Amnesia) 11/22/2006 - "Cognitive effects of SL65.0155, a serotonin 5-HT4 receptor partial agonist, in animal models of amnesia."
4.	Alzheimer Disease (Alzheimer's Disease) 07/01/2008 - "Activation of 5-HT(4) receptors by a selective agonist such as SL65.0155 might therefore provide an opportunity to reduce learning and memory deficits associated with temporal lobe damage, and could be useful for the symptomatic treatment of memory dysfunctions related to pathological aging such as Alzheimer's disease."

Related Drugs and Biologics

1.	5-HT4 Serotonin Receptors
2.	Serotonin (5 Hydroxytryptamine)
3.	Cholinesterase Inhibitors (Anticholinesterases)